12:00 AM
Mar 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

DNA IL-12: Phase II started

OncoSec began an open-label, U.S. Phase II trial to evaluate intratumorally injected DNA IL-12 followed by in vivo electroporation using OncoSec's OMS ElectroImmunotherapy technology on days...

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >